Efficacy of lofexidine for mitigating opioid withdrawal symptoms: results from two randomized, placebo-controlled trials

OBJECTIVES: Fear of opioid withdrawal syndrome (OWS) often dissuades opioid discontinuation. Lofexidine is an FDA-approved, alpha(2)-adrenergic receptor agonist for treatment of OWS. Pivotal trial results from the per-protocol statistical analyses have been published. However, the FDA prescribing in...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Drug Assess
Main Authors: Alam, Danesh, Tirado, Carlos, Pirner, Mark, Clinch, Thomas
Format: Artigo
Sprog:Inglês
Udgivet: Taylor & Francis 2020
Fag:
Addiction Medicine
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6968526/
https://ncbi.nlm.nih.gov/pubmed/32002194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2019.1704416
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker